- News Releases
-
- Nov. 26, 2021 (PDF/201KB)Licensing
- Succession of Manufacturing and Marketing Approval and Marketing Rights of REPLAGAL 3.5 mg for Fabry Disease, an α-Galactosidase Enzyme IV Infusion
-
- Nov. 02, 2021 (PDF/223KB)CSR
- Sumitomo Dainippon Pharma Announces Support for the Recommendations of the Task Force on Climate-related Financial Disclosures (TCFD)
-
- Oct. 27, 2021 (PDF/1,252KB)Finances
- Investors Meeting Presentation for Q2 FY2021 (April 1 to September 30, 2021）
-
- Oct. 27, 2021 (PDF/534KB)Finances
- Supplementary Financial Data (IFRS) for the Second Quarter of the Year Ending March 31, 2022
Other Notices
-
- Nov. 30, 2021Others
- Posted Factbook 2021 ver.2
-
- Nov. 12, 2021CSR (PDF/141KB)
- Sumitomo Dainippon Pharma Receives the Gold Rating in the PRIDE Index for Initiatives Related to LGBTQ for the Second Consecutive Year
-
- Jun. 30, 2021Others
- Posted Factbook 2021
IR Library
-
Change company name from April 2022
-
Continuing to challenge ourselves to support a healthy future for people
-
Aiming to create innovative pharmaceutical products
-
Targeting sustainable growth
-
Thinking BEYOND medication